Q32 Bio Inc. (QTTB)

Q32 Bio Inc. is trading at $15.25, down 4.39% on the session. The 50 day average sits at $14.25 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 50.6, which reads as neutral, and MACD is bearish crossover. Volume is below average.

The nearest support is around $14.79 with resistance near $16.61, so that band frames the current range. Average daily movement is roughly $1.30, or about 8.5% of the share price, which is what any stop placement has to allow for. The overall health score of 53 out of 100 combines a trend score of 75, momentum of 42 and a risk score of 32.

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb – CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.